Novartis to Buy Generic Drug Companies

Published Online: Friday, April 1, 2005

Novartis plans to expand its presence as a maker of generic drugs with the purchase of Hexal of Germany and its New York affiliate, Eon Labs, for a reported $8.4 billion in cash. Hexal is the second-largest generic drug manufacturer in Germany.

The purchase would give Novartis a much bigger piece of the generic drug pie. Hexal would bring Novartis >120 new products, including painkillers and cholesterol drugs. Eon would bring a low-cost copy of a popular antidepressant (bupropion) and an extensive pipeline of new generic drugs.

The acquisition will occur in stages. Novartis already has signed an agreement to pay $7.4 billion for all of Hexal and for 67.7% of Eon. After the transaction closes (scheduled for the second half of 2005), Novartis plans to offer $31 a share, or about $1 billion, for the rest of Eon.

Latest Articles
Mylan has announced the US launch of clozapine orally disintegrating tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical’s FazaClo.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about some safeguards pharmacists can implement.
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Latest Issues